Additionally, clinical data analysis indicated that CCNB1 is closely associated with the clinicopathological characteristics of PCa patients, further supporting the scientific basis for 3-DSC as a potential therapeutic agent. Here, CCNB1 is linked to posterior cortical atrophy.